

Aerobic Oxidative C-H Phosphorylation of Quinoxalines under Catalyst-free Conditions

Qiaoyu Gan,^{a,b} Haibo Liu,^b Zeqi Jiang,^b Junmei Xia,^b Zhenhua Gao,^{b,*} Yongbiao Guo,^{b,*} Hongliang Wen^{a,*}

^a China School of Chemistry & Chemical Engineering, Beijing Institute of Technology, Beijing 102488, P. R. China.

^b State Key Laboratory of NBC Protection for Civilian Research, Beijing 102205, P. R. China.

E-mail: yan87120@126.com; gaozhenhua1223@163.com; wen.hongliang@bit.edu.cn


Supporting Information

Table of Contents

1. Reaction conditions optimization for the Phosphonation of Quinoxalines	2
2. Experimental Section and compound characterization	2
3. NMR spectrum of 3, 5 and 6	20

1. Reaction conditions optimization for the Phosphonation of Quinoxalines

Supplementary Table 1. Selected optimization studies ^[a]




Entry	1a/2a	Solvent	Yield (%)	
			3aa	4aa
1	1/1.1	n-hexane	33	21
2	1/1.1	CCl ₄	70	2
3	1/1.1	toluene	54	10
4	1/1.1	Et ₂ O	36	28
5	1/1.1	CH ₂ Cl ₂	40	2
6	1/1.1	THF	40	10
7	1/1.1	EtOAc	53	14
8	1/1.1	EtOH	9	< 0.1
9	1/1.1	<i>i</i> -PrOH	15	< 0.1
10	1/1.1	MeOH	5	< 0.1
11	1/1.1	1,4-Dioxane	54	8
12	1/1.1	Actone	16	2
13	1/1.1	CH ₃ CN	49	25
14	1/1.1	DMF	16	2
15	1/1.1	DMSO	40	20
16	1/1.1	CHCl ₃	10	< 0.1
17	1/1.1	1,2-dichlorethane	73	< 0.1
18	1/1.1	1-bromo-2-chlorethane	40	1
19 ^c	1/1.1	1,2-dichlorethane	87	< 0.1
20 ^d	1/1.1	1,2-dichlorethane	88	1
21 ^{ce}	1/1.1	1,2-dichlorethane	92(90)	0
22 ^{ce}	1/1.2	1,2-dichlorethane	92	0

^aReaction conditions: **1a** (0.1 mmol) and **2a** (0.11 mmol) in solvent(2 mL) under N₂ for 24 h. ^bYield was determined by HPLC analysis. ^cSolvent (1 mL). ^dSolvent (0.5 mL) ^e under air.


2. Experimental Section and compound characterization

General information: Reagents and solvents were purchased from common commercial suppliers and were used without further purification. Column chromatography was generally performed on silica gel (200-300 mesh). Melting points were determined with a Büchi B-545 melting-point apparatus. 600MHz ¹H NMR and 150MHz ¹³C NMR spectra were recorded on Varian VMS-600 spectrometers, respectively. The chemical shifts are reported in ppm (δ scale) relative to internal tetramethylsilane, and coupling constants are reported in hertz (Hz). High-resolution mass spectra (HRMS) were obtained on Agilent 6502 Q-TOF HPLC and mass spectrometry.


Synthesis of monophosphorylated product 3. A mixture of quinoxalines **1** (0.2 mmol) and diarylphosphine oxides or diphenylphosphonate **2** (0.22 mmol), and 1,2-dichlorethane (2 mL) was stirred at room temperature for 24 h, and directly charged onto silica gel. The product was isolated using hexane/ethyl acetate (2/1~1:2) as eluent.




diphenyl(quinoxalin-2-yl)phosphine oxide (3aa). Yield, 91%; ^1H NMR (600 MHz, CDCl_3) δ 9.64 (s, 1H), 8.25 – 8.19 (m, 1H), 8.17 (d, $J = 7.8$ Hz, 1H), 8.01 – 7.92 (m, 4H), 7.92 – 7.86 (m, 1H), 7.87 – 7.81 (m, 1H), 7.56 (td, $J = 7.4, 1.0$ Hz, 2H), 7.49 (td, $J = 7.6, 3.0$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.54 (d, $J = 124.0$ Hz), 145.66 (d, $J = 22.2$ Hz), 142.43 (d, $J = 17.1$ Hz), 141.73, 132.38, 132.36, 132.33, 132.15 (2), 132.09 (2), 131.53, 130.99, 130.83, 130.24, 129.14, 128.62 (2), 128.53 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.46. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 331.0966, found 331.0958.




(1,2-dihydroquinoxalin-2-yl)diphenylphosphine oxide (3aa'). ^1H NMR (600 MHz, CD_2Cl_2) δ 8.45 (s, 1H), 8.16 (td, $J = 8.5, 1.3$ Hz, 2H), 7.94 (ddd, $J = 14.1, 7.7, 6.4$ Hz, 4H), 7.87 (dtd, $J = 16.7, 6.9, 1.5$ Hz, 2H), 7.73 – 7.66 (m, 5H), 7.65 (s, 1H), 3.54 – 3.32 (m, 1H).




quinoxalin-2-ylbis(4-(trifluoromethyl)phenyl)phosphine oxide (3ab). Yield, 78%; ^1H NMR (600 MHz, CDCl_3) δ 9.70 – 9.66 (m, 1H), 8.22 (dd, $J = 8.4, 1.0$ Hz, 1H), 8.20 – 8.12 (m, 5H), 7.91 (m, 2H), 7.77 (dd, $J = 8.4, 2.2$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 150.48 (d, $J = 127.4$ Hz), 146.20 (d, $J = 22.4$ Hz), 142.91 (d, $J = 2.3$ Hz), 142.11 (d, $J = 17.5$ Hz), 135.28 (d, $J = 102.8$ Hz), 134.73 – 133.93 (m), 132.61, 132.55 (2), 132.49 (2), 131.28, 130.04, 129.79 (d, $J = 1.6$ Hz), 125.66 – 125.55 (m), 125.52 (m), 134.30, 122.49; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 16.79; ^{19}F NMR (282 MHz, CDCl_3) δ -104.94 – -105.62 (m). HRMS (m/z) calcd for $\text{C}_{22}\text{H}_{14}\text{F}_6\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 467.467.0742, found 467.0738.



bis(4-fluorophenyl)(quinoxalin-2-yl)phosphine oxide (3ac). Yield, 80%; ^1H NMR (600 MHz, CDCl_3) δ 9.65 (s, 1H), 8.24 (dd, $J = 8.3, 0.8$ Hz, 1H), 8.16 (dd, $J = 8.3, 1.1$ Hz, 1H), 8.00 – 7.94 (m, 4H), 7.93 – 7.89 (m, 1H), 7.89 – 7.85 (m, 1H), 7.18 (tdd, $J = 6.5, 4.4, 2.2$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 165.40 (dd, $J = 254.6, 3.3$ Hz), 151.93 (d, $J = 126.5$ Hz), 145.73 (d, $J = 22.4$ Hz), 142.28 (d, $J = 17.2$ Hz), 142.11, 134.70 (2), 134.64 (2), 134.63 (2), 134.57 (2), 132.47, 131.15, 130.09, 129.37, 127.10 (dd, $J = 108.7, 3.3$ Hz), 116.31 – 115.93 (4); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 18.94; ^{19}F NMR (282 MHz, CDCl_3) δ -63.30. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{14}\text{F}_2\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 367.0806, found 367.0800.




di([1,1'-biphenyl]-4-yl)(quinoxalin-2-yl)phosphine oxide (3ad). Yield, 70%; ^1H NMR (600 MHz, CDCl_3) δ 9.67 (s, 1H), 8.21 (dd, $J = 17.2, 8.2$ Hz, 2H), 8.04 (dd, $J = 11.6, 8.2$ Hz, 4H), 7.86 (dt, $J = 14.6, 7.0$ Hz, 2H), 7.70 (dd, $J = 7.9, 2.1$ Hz, 4H), 7.62 – 7.54 (m, 4H), 7.42 (t, $J = 7.6$ Hz, 4H), 7.36 (dd, $J = 8.2, 6.5$ Hz, 2H); ^{13}C NMR (151 MHz, CDCl_3) δ 171.15, 152.55 (d, $J = 124.8$ Hz), 145.86 (d, $J = 22.2$ Hz), 145.21 (d, $J = 2.6$ Hz), 142.46 (d, $J = 17.0$ Hz), 141.97, 139.81, 132.69 (2), 132.63 (2), 132.30, 131.00, 130.26, 129.80 (d, $J = 106.4$ Hz), 129.29, 128.96 (4), 128.24, 127.35(2), 127.29 (4), 127.27 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.43. HRMS (m/z) calcd for $\text{C}_{32}\text{H}_{24}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 483.1621, found 483.1624.




quinoxalin-2-yl-di-p-tolylphosphine oxide (3ae). Yield, 60%; ^1H NMR (600 MHz, CDCl_3) δ 9.60 (s, 1H), 8.25 (d, $J = 8.4$ Hz, 1H), 8.17 (dd, $J = 8.3, 0.7$ Hz, 1H), 7.91 – 7.87 (m, 1H), 7.85 (dd, $J = 8.3, 1.3$ Hz, 1H), 7.81 (dd, $J = 12.0, 8.1$ Hz, 4H), 7.29 (dd, $J = 8.0, 2.7$ Hz, 4H), 2.40 (s, 6H); ^{13}C NMR (151


MHz, CDCl₃) δ 153.12 (d, *J* = 123.6 Hz), 145.40 (d, *J* = 22.3 Hz), 142.97 (d, *J* = 2.8 Hz), 142.54 (d, *J* = 16.9 Hz), 141.35, 132.31, 132.19 (2), 132.13 (2), 130.97, 130.26, 129.37 (2), 129.29 (2), 128.94, 127.92 (d, *J* = 107.8 Hz), 21.65, 21.64; ³¹P NMR (243 MHz, CDCl₃): δ (ppm) 21.41. HRMS (*m/z*) calcd for C₂₂H₂₀N₂OP[M+H]⁺ 359.1308, found 359.1307.



bis(4-(tert-butyl)phenyl)(quinoxalin-2-yl)phosphine oxide (3af). Yield, 67%; ¹H NMR (600 MHz, CDCl₃) δ 9.61 (s, 1H), 8.27 (d, *J* = 8.2 Hz, 1H), 8.22 (d, *J* = 8.1 Hz, 1H), 7.89 (dd, *J* = 11.9, 8.4 Hz, 6H), 7.50 (dd, *J* = 8.3, 2.6 Hz, 4H), 1.31 (s, 18H); ¹³C NMR (151 MHz, CDCl₃) δ 155.89, 155.87, 153.32 (d, *J* = 123.2 Hz), 145.22 (d, *J* = 22.4 Hz), 142.62 (d, *J* = 16.8 Hz), 141.09, 132.38, 132.04 (2), 131.97 (2), 131.02, 130.31, 128.80, 127.87 (d, *J* = 107.8 Hz), 125.67 (2), 125.59 (2), 35.05 (2), 31.05 (6); ³¹P NMR (243 MHz, CDCl₃): δ (ppm) 20.43. HRMS (*m/z*) calcd for C₂₈H₃₂N₂OP[M+H]⁺ 443.2247, found 433.2252.




bis(4-(tert-butyl)phenyl)(quinoxalin-2-yl)phosphine oxide (3ag). Yield, 67%; ¹H NMR (600 MHz, CDCl₃) δ 9.60 (s, 1H), 8.31 – 8.24 (m, 1H), 8.17 (d, *J* = 7.6 Hz, 1H), 7.91 – 7.87 (m, 1H), 7.87 – 7.81 (m, 5H), 6.98 (dd, *J* = 8.8, 2.3 Hz, 4H), 3.84 (s, 6H); ¹³C NMR (151 MHz, CDCl₃) δ 162.85, 162.83, 153.40 (d, *J* = 124.5 Hz), 145.20 (d, *J* = 22.3 Hz), 142.57 (d, *J* = 16.9 Hz), 141.12, 134.11 (2), 134.04 (2), 132.35, 131.02, 130.23, 128.82, 122.25 (d, *J* = 112.4 Hz), 114.24 (2), 114.15 (2), 55.36 (2); ³¹P NMR (243 MHz, CDCl₃): δ (ppm) 21.54. HRMS (*m/z*) calcd for C₂₂H₂₀N₂O₃P[M+H]⁺ 391.1206, found 391.1210.




quinoxalin-2-yl-di-o-tolylphosphine oxide (3ah). Yield, 56%; ¹H NMR (600 MHz, CDCl₃) δ 9.56 (s,


1H), 8.28 (dd, $J = 8.4, 0.7$ Hz, 1H), 8.16 – 8.08 (m, 1H), 7.91 (ddd, $J = 8.4, 7.0, 1.3$ Hz, 1H), 7.85 (ddd, $J = 8.3, 7.0, 1.3$ Hz, 1H), 7.47 (dd, $J = 10.6, 4.4$ Hz, 2H), 7.44 – 7.38 (m, 2H), 7.31 (dd, $J = 7.5, 4.5$ Hz, 2H), 7.24 – 7.18 (m, 2H), 2.48 (s, 6H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.04 (d, $J = 122.6$ Hz), 146.20 (d, $J = 22.9$ Hz), 143.11 (d, $J = 8.6$ Hz), 142.29 (d, $J = 17.0$ Hz), 141.32, 133.08 (d, $J = 12.0$ Hz, 2C), 132.49 (d, $J = 2.6$ Hz, 2C), 132.40, 131.99 (d, $J = 11.0$ Hz, 2C), 131.00, 130.38, 129.38 (d, $J = 103.0$ Hz), 128.96, 125.62 (d, $J = 12.9$ Hz, 2C), 21.89 (d, $J = 4.2$ Hz, 2C); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 29.81. HRMS (m/z) calcd for $\text{C}_{22}\text{H}_{20}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 359.1308, found 359.1310.



bis(2-methoxyphenyl)(quinoxalin-2-yl)phosphine oxide (3ai). Yield, 80%; ^1H NMR (600 MHz, CDCl_3) δ 8.93 (s, 1H), 8.37 – 8.31 (m, 2H), 7.95 – 7.85 (m, 2H), 7.75 (ddd, $J = 14.3, 7.6, 1.6$ Hz, 2H), 7.61 (dd, $J = 11.6, 4.1$ Hz, 2H), 7.13 (td, $J = 7.5, 1.7$ Hz, 2H), 6.95 (dd, $J = 8.2, 5.6$ Hz, 2H), 3.58 (s, 6H); ^{13}C NMR (151 MHz, CDCl_3) δ 160.71 (d, $J = 2.9$ Hz, 2C), 155.60 (d, $J = 131.4$ Hz), 143.78 (d, $J = 29.8$ Hz), 143.33 (d, $J = 17.2$ Hz), 137.66, 135.08, 135.07, 134.86 (d, $J = 7.9$ Hz, 2C), 132.60, 131.16, 130.63, 126.87, 121.40 (d, $J = 12.4$ Hz, 2C), 117.71 (d, $J = 109.1$ Hz, 2C), 111.25 (d, $J = 6.6$ Hz, 2C), 55.56 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 18.47. HRMS (m/z) calcd for $\text{C}_{22}\text{H}_{20}\text{N}_2\text{O}_3\text{P}[\text{M}+\text{H}]^+$ 391.1206, found 391.1200.




bis(3,5-dimethylphenyl)(quinoxalin-2-yl)phosphine oxide (3aj). Yield, 88%; ^1H NMR (600 MHz, CDCl_3) δ 9.58 (s, 1H), 8.27 (dd, $J = 8.4, 1.0$ Hz, 1H), 8.21 (dd, $J = 8.3, 1.0$ Hz, 1H), 7.93 – 7.88 (m, 1H), 7.86 (ddd, $J = 8.3, 7.0, 1.4$ Hz, 1H), 7.53 (s, 2H), 7.51 (s, 2H), 7.18 (s, 2H), 2.33 (s, 12H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.16 (d, $J = 122.5$ Hz), 145.40 (d, $J = 22.3$ Hz), 142.63 (d, $J = 16.8$ Hz), 141.25, 138.40 (2), 138.31 (2), 134.21 (d, $J = 2.8$ Hz), 132.34, 130.99, 130.76 (d, $J = 104.2$ Hz), 130.34, 129.69 (2), 129.62 (2), 128.88, 21.33 (4); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 21.87. HRMS (m/z) calcd for $\text{C}_{24}\text{H}_{24}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 387.1621, found 387.1625.




3ak

bis(3,5-di-tert-butylphenyl)(quinoxalin-2-yl)phosphine oxide (3ak). Yield, 80%; ^1H NMR (600 MHz, CDCl_3) δ 9.63 (s, 1H), 8.28 (dd, $J = 8.2, 1.1$ Hz, 1H), 8.18 (dd, $J = 8.2, 1.4$ Hz, 1H), 7.97 (d, $J = 1.8$ Hz, 2H), 7.95 (d, $J = 1.8$ Hz, 2H), 7.91 – 7.85 (m, 2H), 7.60 (d, $J = 0.9$ Hz, 2H), 1.31 (s, 36H); ^{13}C NMR (151 MHz, CDCl_3) δ 154.29 (d, $J = 119.7$ Hz), 151.08 (2), 151.00 (2), 144.99, 142.74, 140.90, 132.25, 131.14, 130.65, 129.97 (2), 128.76, 126.45 (2), 126.35 (2), 126.28 (2), 35.13 (4), 31.35 (12); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 19.20. HRMS (m/z) calcd for $\text{C}_{36}\text{H}_{48}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 555.3499, found 555.3500.




3am

di(naphthalen-2-yl)(quinoxalin-2-yl)phosphine oxide (3am). Yield, 70%; ^1H NMR (600 MHz, CDCl_3) δ 9.66 (s, 1H), 8.72 (d, $J = 8.5$ Hz, 2H), 8.24 (d, $J = 8.4$ Hz, 1H), 8.07 (d, $J = 8.3$ Hz, 2H), 8.00 (d, $J = 8.4$ Hz, 1H), 7.92 (d, $J = 8.2$ Hz, 2H), 7.90 – 7.83 (m, 1H), 7.81 – 7.75 (m, 1H), 7.69 (dd, $J = 16.2, 7.1$ Hz, 2H), 7.53 – 7.48 (m, 2H), 7.46 – 7.39 (m, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.99 (d, $J = 124.3$ Hz), 146.18 (d, $J = 23.4$ Hz), 142.30 (d, $J = 17.2$ Hz), 141.47, 134.11, 134.04, 133.90 (d, $J = 9.6$ Hz), 133.85 (2), 133.83 (2), 133.74 (d, $J = 8.6$ Hz), 132.39, 130.93, 130.41, 128.95 (2), 127.58 (d, $J = 3.6$ Hz), 127.30 (d, $J = 5.2$ Hz), 126.90 (2), 126.58 (2), 124.54, 124.44; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 30.62. HRMS (m/z) calcd for $\text{C}_{28}\text{H}_{20}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 431.1308, found 431.1315.




3an

di(naphthalen-1-yl)(quinoxalin-2-yl)phosphine oxide (3an). Yield, 85%; ^1H NMR (600 MHz, CDCl_3) δ 9.73 (s, 1H), 8.58 (d, $J = 14.2$ Hz, 2H), 8.26 (d, $J = 8.3$ Hz, 1H), 8.19 (d, $J = 8.4$ Hz, 1H), 8.01 – 7.83 (m, 10H), 7.65 – 7.58 (m, 2H), 7.58 – 7.52 (m, 2H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.64 (d, $J = 124.5$ Hz), 145.80 (d, $J = 22.3$ Hz), 142.50 (d, $J = 17.0$ Hz), 141.81, 134.92 (d, $J = 2.3$ Hz), 134.39, 134.33, 132.47, 132.38, 131.04, 130.26, 129.18, 129.09 (2), 128.53 (2), 128.49, 128.41, 128.30 (d, $J = 105.6$ Hz), 127.85 (2), 127.03 (2), 126.83, 126.76 ; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 21.32. HRMS (m/z) calcd for $\text{C}_{28}\text{H}_{20}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 431.1308, found 431.1311.




3ao

ethyl phenyl(quinoxalin-2-yl)phosphinate (3ao). Yield, 76%; ^1H NMR (600 MHz, CDCl_3) δ 9.44 (s, 1H), 8.21 – 8.15 (m, 1H), 8.13 (dd, $J = 8.3, 1.0$ Hz, 1H), 8.07 – 7.99 (m, 2H), 7.82 (dtd, $J = 16.6, 6.9, 1.4$ Hz, 2H), 7.59 – 7.53 (m, 1H), 7.48 (td, $J = 7.6, 3.7$ Hz, 2H), 4.35 – 4.12 (m, 2H), 1.42 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 150.68 (d, $J = 161.6$ Hz), 146.26 (d, $J = 24.9$ Hz), 142.81 (d, $J = 2.4$ Hz), 142.47 (d, $J = 18.6$ Hz), 132.90 (d, $J = 2.8$ Hz), 132.43, 132.36, 132.02, 130.71, 130.32 (d, $J = 0.9$ Hz), 129.49 (d, $J = 1.9$ Hz), 129.39 (d, $J = 140.0$ Hz), 128.66, 128.57, 62.29 (d, $J = 6.3$ Hz), 16.56 (d, $J = 6.3$ Hz); ^{31}P NMR (243 MHz, CDCl_3) δ 24.30; HRMS (m/z) calcd for $\text{C}_{16}\text{H}_{16}\text{N}_2\text{O}_2\text{P}[\text{M}+\text{H}]^+$ 299.0945, found 299.0950.



3ap


ethyl methyl(quinoxalin-2-yl)phosphinate (3ap). Yield, 67%; ^1H NMR (600 MHz, CDCl_3) δ 9.42 (s, 1H), 8.25 – 8.11 (m, 2H), 7.97 – 7.72 (m, 2H), 4.29 – 4.14 (m, 1H), 4.04 – 3.91 (m, 1H), 1.92 (d, $J = 15.1$ Hz, 3H), 1.31 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 150.29 (d, $J = 152.0$ Hz), 145.74 (d, $J = 23.7$ Hz), 143.07 (d, $J = 2.4$ Hz), 142.36 (d, $J = 18.6$ Hz), 132.06 (s), 130.86 (s), 130.07 (d, $J = 1.0$ Hz), 129.57 (d, $J = 1.9$ Hz), 61.63 (d, $J = 6.5$ Hz), 16.42 (d, $J = 6.3$ Hz), 13.67 (d, $J = 104.3$ Hz); ^{31}P NMR (243 MHz, CDCl_3) δ 39.24 (s); HRMS (m/z) calcd for $\text{C}_{11}\text{H}_{14}\text{N}_2\text{O}_2\text{P}[\text{M}+\text{H}]^+$ 237.0788, found 237.0797.




3aq

diphenyl quinoxalin-2-ylphosphonate (3aq). Yield, 70%; ^1H NMR (600 MHz, CDCl_3) δ 9.42 (s, 1H),


8.34 – 8.28 (m, 1H), 8.20 (dd, $J = 8.3, 1.2$ Hz, 1H), 7.95-7.89 (m, 2H), 7.35 – 7.29 (m, 8H), 7.20 – 7.16 (m, 2H); ^{13}C NMR (151 MHz, CDCl_3) δ 150.03 (d, $J = 8.0$ Hz), 147.00, 145.48, 146.31 (d, $J = 29.7$ Hz), 143.07 (d, $J = 2.8$ Hz), 142.42 (d, $J = 22.5$ Hz), 132.75, 131.22, 130.45 (d, $J = 1.5$ Hz), 129.86 (4), 129.53 (d, $J = 2.3$ Hz), 125.61 (2), 120.78 (2), 120.75 (2). ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 0.96. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_3\text{P}[\text{M}+\text{H}]^+$ 363.0893, found 363.0890.



(3-chloro-7-fluoroquinoxalin-2-yl)diphenylphosphine oxide (3ca). Yield, 47%; ^1H NMR (600 MHz, CDCl_3) δ 8.07 (dd, $J = 9.2, 5.4$ Hz, 1H), 7.79 (dd, $J = 12.2, 7.6$ Hz, 4H), 7.69 – 7.64 (m, 1H), 7.64 – 7.58 (m, 3H), 7.53 (td, $J = 7.5, 2.7$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 162.97 (d, $J = 255.3$ Hz), 151.36 (d, $J = 126.7$ Hz), 148.09, 140.66, 140.66, 139.13, 132.71 (d, $J = 2.3$ Hz), 132.14 (2), 132.08 (2), 130.43 (d, $J = 9.8$ Hz), 129.54 (d, $J = 109.8$ Hz), 128.72 (2), 128.64 (2), 123.73 (d, $J = 26.2$ Hz), 113.74 (d, $J = 21.7$ Hz), 110.08 (d, $J = 209.3$ Hz); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 29.46. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{14}\text{ClFN}_2\text{OP}[\text{M}+\text{H}]^+$ 383.0511, found 383.0510.




(3,7-dichloroquinoxalin-2-yl)diphenylphosphine oxide (3da). Yield, 81%; ^1H NMR (600 MHz, CDCl_3) ^1H NMR (600 MHz, CDCl_3) δ 7.99 (d, $J = 9.0$ Hz, 1H), 7.95 (d, $J = 2.2$ Hz, 1H), 7.83 – 7.75 (m, 5H), 7.61 (td, $J = 7.5, 1.1$ Hz, 2H), 7.52 (td, $J = 7.7, 3.1$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.11 (d, $J = 124.9$ Hz), 149.02 (d, $J = 21.3$ Hz), 140.30, 140.03 (d, $J = 15.8$ Hz), 136.66, 134.03 (2), 132.46, 134.44, 132.07 (2), 132.01 (2), 130.22 (d, $J = 109.2$ Hz), 129.46 (d, $J = 1.6$ Hz), 128.87, 128.57 (2), 128.49 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 27.67. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{14}\text{Cl}_2\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 399.0215, found 399.0210.




(7-bromo-3-chloroquinoxalin-2-yl)diphenylphosphine oxide (3ea). Yield, 54%; ^1H NMR (600 MHz, CDCl_3) δ 8.23 (d, $J = 1.9$ Hz, 1H), 7.87 – 7.76 (m, 6H), 7.60 (dd, $J = 10.7, 4.2$ Hz, 2H), 7.51 (td, $J = 7.7, 3.0$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 151.29 (d, $J = 125.6$ Hz), 149.81 (d, $J = 21.2$ Hz), 142.22, 138.63 (d, $J = 15.7$ Hz), 134.36, 132.41 (d, $J = 2.7$ Hz), 132.08 (2), 132.01 (2), 131.23,


130.64, 129.93, 128.56 (2), 128.48 (2), 127.76; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 27.59. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{14}\text{BrClN}_2\text{OP}[\text{M}+\text{H}]^+$ 442.9710, found 442.9705.




(6-bromo-3-chloroquinoxalin-2-yl)diphenylphosphine oxide (3fa). Yield, 59%; ^1H NMR (600 MHz, CDCl_3) δ 8.23 (d, $J = 1.9$ Hz, 1H), 7.87 – 7.76 (m, 6H), 7.60 (dd, $J = 10.7, 4.2$ Hz, 2H), 7.51 (td, $J = 7.7, 3.0$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.00 (d, $J = 125.0$ Hz), 149.10 (d, $J = 21.6$ Hz), 140.57, 140.27 (d, $J = 15.7$ Hz), 136.58 (2), 132.48, 132.46, 132.24, 132.08 (2), 132.01 (2), 130.12 (d, $J = 109.2$ Hz), 129.51, 128.60 (2), 128.51 (2), 124.76; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 27.87. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{14}\text{BrClN}_2\text{OP}[\text{M}+\text{H}]^+$ 442.9710, found 442.9715.




1-(3-(diphenylphosphoryl)quinoxalin-2-yl)ethan-1-one (3ga). Yield, 66%; ^1H NMR (600 MHz, CDCl_3) δ 8.18 – 8.13 (m, 1H), 8.02 (d, $J = 8.3$ Hz, 1H), 7.92 – 7.87 (m, 1H), 7.87 – 7.81 (m, 5H), 7.54 (td, $J = 7.4, 1.3$ Hz, 2H), 7.50 – 7.44 (m, 4H), 2.84 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 199.22, 170.15, 152.62 (d, $J = 19.5$ Hz), 149.91 (d, $J = 122.9$ Hz), 140.29 (d, $J = 16.9$ Hz), 139.03, 131.51, 131.34, 131.10 (2), 131.03 (2), 130.89, 130.87, 130.78, 130.62, 129.01, 128.65 (d, $J = 1.8$ Hz), 127.29 (2), 127.20 (2), 26.65; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 24.99. HRMS (m/z) calcd for $\text{C}_{22}\text{H}_{18}\text{N}_2\text{O}_2\text{P}[\text{M}+\text{H}]^+$ 373.1100, found 373.1109.




(3-methylquinoxalin-2-yl)diphenylphosphine oxide (3ha). Yield, 35%; ^1H NMR (600 MHz, CDCl_3) δ 7.99 (d, $J = 8.4$ Hz, 1H), 7.73 (d, $J = 8.3$ Hz, 1H), 7.61 (dd, $J = 11.3, 4.0$ Hz, 1H), 7.56 (dd, $J = 12.0, 7.3$ Hz, 4H), 7.50 (t, $J = 7.6$ Hz, 1H), 7.32 (td, $J = 7.4, 0.9$ Hz, 2H), 7.24 (td, $J = 7.7, 3.0$ Hz, 4H), 2.83 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 155.89 (d, $J = 22.9$ Hz), 152.42 (d, $J = 123.5$ Hz), 140.40 (d, $J = 17.5$ Hz), 139.24, 132.83, 132.27, 132.25, 132.17 (2), 132.11 (2), 131.16 (d, $J = 106.2$ Hz), 130.15, 130.05, 128.54 (2), 128.46 (2), 127.19, 22.75. ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 27.10. HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 345.1151, found 345.1153.




(3-aminoquinoxalin-2-yl)diphenylphosphine oxide (3ia). Yield, 89%; ^1H NMR (600 MHz, CDCl_3) δ 7.98 – 7.92 (m, 4H), 7.87 (d, $J = 8.3$ Hz, 1H), 7.70 – 7.64 (m, 2H), 7.59 (td, $J = 7.4, 1.2$ Hz, 2H), 7.50 (td, $J = 7.7, 3.3$ Hz, 4H), 7.43 (ddd, $J = 8.3, 6.0, 2.3$ Hz, 1H); ^{13}C ^{13}C NMR (151 MHz, CDCl_3) δ 153.19 (d, $J = 20.8$ Hz), 141.85 (d, $J = 124.9$ Hz), 136.70 (d, $J = 17.2$ Hz), 133.23, 132.63, 132.61, 132.17 (d, $J = 9.4$ Hz), 132.16 (2), 132.10 (2), 130.67 (d, $J = 106.6$ Hz), 129.97, 128.65 (2), 128.57 (2), 125.68, 123.71; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 26.07. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{17}\text{N}_3\text{OP}[\text{M}+\text{H}]^+$ 346.1104, found 346.1102.




(5,8-dibromoquinoxalin-2-yl)diphenylphosphine oxide (3ja). Yield, 61%; ^1H NMR (600 MHz, CDCl_3) δ 9.77 (s, 1H), 8.17 – 8.09 (m, 4H), 8.03 (m, 2H), 7.58 – 7.53 (m, 2H), 7.53 – 7.47 (m, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 154.31 (d, $J = 121.2$ Hz), 147.44, 147.30, 141.31 (d, $J = 2.3$ Hz), 140.63 (d, $J = 16.5$ Hz), 135.17, 134.11, 132.39, 132.37, 132.13 (2), 132.06 (2), 131.05 (d, $J = 105.2$ Hz), 128.65 (2), 128.57 (2), 125.00, 124.15 (d, $J = 2.5$ Hz). ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 17.38. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{14}\text{Br}_2\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 486.9205, found 486.9200.




(6,7-dichloroquinoxalin-2-yl)diphenylphosphine oxide (3ka). Yield, 67%; ^1H NMR (600 MHz, CDCl_3) δ 9.63 (s, 1H), 8.29 (d, $J = 6.1$ Hz, 2H), 7.96 – 7.85 (m, 4H), 7.61 – 7.53 (m, 2H), 7.50 (m, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.74 (d, $J = 121.2$ Hz), 147.42, 147.28, 141.33 (d, $J = 1.8$ Hz), 140.70 (d, $J = 17.4$ Hz), 136.89, 135.76, 132.52, 132.50, 132.10 (2), 132.04 (2), 130.87 (d, $J = 105.3$ Hz), 130.52, 130.21 (d, $J = 1.8$ Hz), 128.68 (2), 128.60 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 17.38. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{14}\text{Cl}_2\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 399.0215, found 399.0211.




3-(diphenylphosphoryl)quinoxaline-5-carboxylic acid (3la-1). Yield, 48%; ^1H NMR (600 MHz, CDCl_3) δ 13.41 (s, 1H), 9.78 (s, 1H), 8.88 (d, $J = 7.2$ Hz, 1H), 8.47 (d, $J = 8.3$ Hz, 1H), 8.08 (t, $J = 7.9$ Hz, 1H), 7.81 (dd, $J = 12.2, 7.7$ Hz, 4H), 7.67 (t, $J = 7.3$ Hz, 2H), 7.57 (td, $J = 7.5, 2.7$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 151.55 (d, $J = 113.6$ Hz), 147.70 (d, $J = 19.4$ Hz), 143.10, 138.71 (d, $J = 14.1$ Hz), 137.02, 135.10, 133.43, 133.41, 132.38, 132.02 (2), 131.95 (2), 129.33 (2), 129.24 (2), 129.02 (d, $J = 106.7$ Hz), 125.35; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 24.87. HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{15}\text{N}_2\text{O}_3\text{P}[\text{M}+\text{H}]^+$ 375.0893, found 375.0899.




2-(diphenylphosphoryl)quinoxaline-5-carboxylic acid (3la-2). Yield, 48%; ^1H NMR (600 MHz, CDCl_3) δ 9.67 (s, 1H), 8.95 (dd, $J = 7.3, 1.0$ Hz, 1H), 8.45 (d, $J = 8.4$ Hz, 1H), 8.09 – 8.02 (m, 1H), 7.96 (dd, $J = 12.0, 7.6$ Hz, 4H), 7.60 (t, $J = 7.3$ Hz, 2H), 7.52 (td, $J = 7.6, 2.8$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 151.55 (d, $J = 113.6$ Hz), 147.70 (d, $J = 19.4$ Hz), 143.10, 138.71 (d, $J = 14.1$ Hz), 137.02, 135.10, 133.43, 133.41, 132.38, 132.02 (2), 131.95 (2), 129.33 (2), 129.24 (2), 129.02 (d, $J = 106.7$ Hz), 125.35; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.26. HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{15}\text{N}_2\text{O}_3\text{P}[\text{M}+\text{H}]^+$ 375.0893, found 375.0897.




(8-chloroquinoxalin-2-yl)diphenylphosphine oxide (3ma-1). Yield, 71%; ^1H NMR (600 MHz, CDCl_3) δ 9.70 (s, 1H), 8.10 (dd, $J = 8.5, 1.1$ Hz, 1H), 7.97 (dd, $J = 7.5, 1.2$ Hz, 1H), 7.96 – 7.91 (m, 4H), 7.76 (dd, $J = 8.4, 7.6$ Hz, 1H), 7.59 – 7.55 (m, 2H), 7.49 (ddd, $J = 7.4, 4.0, 2.4$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.44 (d, $J = 122.2$ Hz), 146.73 (d, $J = 22.1$ Hz), 143.07 (d, $J = 17.0$ Hz), 139.50 (d, $J = 2.4$ Hz), 133.60 (d, $J = 2.3$ Hz), 132.45, 132.43, 132.17 (2), 132.10 (2), 131.72, 131.04 (d, $J = 105.2$ Hz), 130.42, 129.28, 128.65 (2), 128.57 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.56. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{15}\text{ClN}_2\text{OP}[\text{M}+\text{H}]^+$ 365.0605, found 365.0600.




(5-chloroquinoxalin-2-yl)diphenylphosphine oxide (3ma-2). Yield, 71%; ^1H NMR (600 MHz, CDCl_3) δ 9.73 (s, 1H), 8.12 (ddd, $J = 11.0, 9.1, 4.1$ Hz, 5H), 7.94 (dd, $J = 7.5, 1.1$ Hz, 1H), 7.79 (dd, $J = 8.3, 7.8$ Hz, 1H), 7.57 – 7.52 (m, 2H), 7.52 – 7.46 (m, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.90 (d, $J = 123.2$ Hz), 146.82 (d, $J = 21.5$ Hz), 143.59 (d, $J = 2.2$ Hz), 138.97 (d, $J = 16.6$ Hz), 134.36, 132.29, 132.27, 132.09 (2), 132.03 (2), 131.60, 131.35 (d, $J = 104.8$ Hz), 130.57, 128.65 (d, $J = 1.7$ Hz), 128.61 (2), 128.53 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 17.65. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{15}\text{ClN}_2\text{OP}[\text{M}+\text{H}]^+$ 365.0605, found 365.0607.



(8-bromoquinoxalin-2-yl)diphenylphosphine oxide (3na-1). Yield, 91%; ^1H NMR (600 MHz, CDCl_3) δ 9.68 (s, 1H), 8.18 (dd, $J = 7.5, 1.1$ Hz, 1H), 8.14 (dd, $J = 8.5, 0.9$ Hz, 1H), 7.96 – 7.90 (m, 4H), 7.69 (dd, $J = 8.3, 7.7$ Hz, 1H), 7.57 (td, $J = 7.4, 1.2$ Hz, 2H), 7.49 (td, $J = 7.6, 3.1$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.39 (d, $J = 122.3$ Hz), 147.00 (d, $J = 22.2$ Hz), 143.13 (d, $J = 17.1$ Hz), 140.40 (d, $J = 2.2$ Hz), 135.30, 132.46, 132.44, 132.17 (2), 132.10 (2), 131.01 (d, $J = 105.3$ Hz), 130.99, 130.04, 128.66 (2), 128.58 (2), 124.51 (d, $J = 2.6$ Hz); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.58. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{15}\text{BrN}_2\text{OP}[\text{M}+\text{H}]^+$ 409.0100, found 409.0110.




(5-bromoquinoxalin-2-yl)diphenylphosphine oxide (3na-2). Yield, 91%; ^1H NMR (600 MHz, CDCl_3) δ 9.70 (s, 1H), 8.16 (dt, $J = 10.3, 4.7$ Hz, 6H), 7.73 (t, $J = 8.0$ Hz, 1H), 7.55 (td, $J = 7.4, 1.3$ Hz, 2H), 7.50 (ddd, $J = 7.2, 5.4, 2.6$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.13 (d, $J = 124.0$ Hz), 146.77 (d, $J = 21.4$ Hz), 143.65, 139.85 (d, $J = 16.6$ Hz), 134.14, 132.32, 132.30, 132.17, 132.13 (2), 132.07(2), 131.21 (d, $J = 104.9$ Hz), 129.40, 128.63 (2), 128.55 (2), 125.41; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 17.48. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{15}\text{BrN}_2\text{OP}[\text{M}+\text{H}]^+$ 409.0100, found 409.0108.




3oa-1

(8-methylquinoxalin-2-yl)diphenylphosphine oxide (3oa-1) Yield, 88%; ^1H NMR (600 MHz, CDCl_3) δ 9.60 (s, 1H), 7.99 (dd, $J = 7.6, 2.1$ Hz, 1H), 7.98 – 7.92 (m, 4H), 7.74 – 7.68 (m, 2H), 7.55 (td, $J = 7.4, 1.2$ Hz, 2H), 7.48 (td, $J = 7.6, 3.0$ Hz, 4H), 2.83 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 151.56 (d, $J = 124.9$ Hz), 145.12 (d, $J = 22.3$ Hz), 142.43 (d, $J = 17.0$ Hz), 141.71, 138.02, 132.26, 132.25, 132.17 (2), 132.11 (2), 131.87, 131.80, 131.10, 130.51, 128.56 (2), 128.48 (2), 128.04, 17.29; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.71; HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 345.1151, found 345.1148.




3oa-2

(5-methylquinoxalin-2-yl)diphenylphosphine oxide (3oa-2). Yield, 88%; ^1H NMR (600 MHz, CDCl_3) δ 9.64 (s, 1H), 8.09 (d, $J = 8.5$ Hz, 1H), 8.03 – 7.93 (m, 4H), 7.83 – 7.75 (m, 1H), 7.69 (d, $J = 7.0$ Hz, 1H), 7.56 (td, $J = 7.4, 1.3$ Hz, 2H), 7.52 – 7.44 (m, 4H), 2.75 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 150.98 (d, $J = 125.6$ Hz), 145.10 (d, $J = 22.4$ Hz), 141.62 (d, $J = 16.4$ Hz), 138.57, 132.37, 132.29, 132.27, 132.12 (2), 132.06 (2), 131.46 (d, $J = 104.9$ Hz), 130.95, 128.54 (2), 128.46 (2), 126.78, 126.78, 17.11; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.20; HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 345.1151, found 345.1147.




3pa-1


(8-hydroxyquinoxalin-2-yl)diphenylphosphine oxide (3pa-1). Yield, 60%; ^1H NMR (600 MHz, CDCl_3) δ 9.53 (s, 1H), 8.00 – 7.93 (m, 4H), 7.77 – 7.72 (m, 1H), 7.69 (d, $J = 8.4$ Hz, 1H), 7.59 – 7.54 (m, 2H), 7.49 (td, $J = 7.6, 3.0$ Hz, 4H), 7.33 (d, $J = 7.5$ Hz, 1H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.13 (d, $J = 124.4$ Hz), 152.11, 143.75 (d, $J = 22.6$ Hz), 142.62 (d, $J = 17.4$ Hz), 132.41, 132.40, 132.15 (2), 132.08 (2), 131.99, 131.46, 130.76, 128.63 (2), 128.55 (2), 120.45, 112.77; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.73; HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_2\text{P}[\text{M}+\text{H}]^+$ 347.0944, found 347.0945.



(5-hydroxyquinoxalin-2-yl)diphenylphosphine oxide (3pa-2). Yield, 60%; ^1H NMR (600 MHz, CDCl_3) δ 9.54 (s, 1H), 7.82 (dt, $J = 7.7, 7.0$ Hz, 5H), 7.73 (d, $J = 8.3$ Hz, 1H), 7.61 (t, $J = 7.0$ Hz, 2H), 7.52 (td, $J = 7.6, 2.9$ Hz, 4H), 7.29 (d, $J = 7.7$ Hz, 1H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.36, 149.14 (d, $J = 122.1$ Hz), 147.12 (d, $J = 22.0$ Hz), 143.00, 133.80, 132.71 (d, $J = 2.4$ Hz), 132.15 (2), 132.08 (2), 130.62 (d, $J = 105.5$ Hz), 128.93, 128.83 (2), 128.75 (2), 119.91, 112.02 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 23.42; HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{O}_2\text{P}[\text{M}+\text{H}]^+$ 347.0944, found 347.0947.




2 or 3-(diphenylphosphoryl)quinoxaline-6-carbaldehyde (3qa). Yield, 80%; ^1H NMR (600 MHz, CDCl_3) δ 10.29 (s, 1H), 9.75 (s, 1H), 8.65 (s, 1H), 8.37 – 8.23 (m, 2H), 7.97 (dd, $J = 11.9, 7.8$ Hz, 4H), 7.59 (t, $J = 7.3$ Hz, 2H), 7.51 (dd, $J = 9.8, 4.9$ Hz, 4H); ^1H NMR (600 MHz, CDCl_3) δ 10.27 (s, 1H), 9.75 (s, 1H), 8.64 (s, 1H), 8.37 – 8.23 (m, 2H), 7.97 (dd, $J = 11.9, 7.8$ Hz, 4H), 7.59 (t, $J = 7.3$ Hz, 2H), 7.51 (dd, $J = 9.8, 4.9$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 190.98, 190.83, 148.51 (d, $J = 21.5$ Hz), 147.55 (d, $J = 21.7$ Hz), 145.43, 144.79 (d, $J = 16.9$ Hz), 142.48 (d, $J = 2.1$ Hz), 141.84 (d, $J = 16.9$ Hz), 138.27, 137.53, 135.21, 135.10, 132.60, 132.58, 132.17 (2), 132.15 (2), 132.10 (2), 132.09 (2), 131.46, 131.12, 131.06, 130.42, 130.37, 128.73 (2), 128.65 (2), 127.32; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.73 or 20.63; HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{16}\text{N}_2\text{O}_2\text{P}[\text{M}+\text{H}]^+$ 359.0944, found 359.0948.




2 or 3-(diphenylphosphoryl)quinoxaline-6-carboxylic acid (3ra). Yield, 80%; ^1H NMR (600 MHz, CDCl_3) δ 9.77 (s, 1H), 8.94 (d, $J = 1.7$ Hz, 1H), 8.48 (dd, $J = 8.8, 1.8$ Hz, 1H), 8.26 (d, $J = 8.8$ Hz, 1H), 8.03 – 7.95 (m, 4H), 7.58 (dd, $J = 10.4, 4.4$ Hz, 2H), 7.51 (td, $J = 7.6, 3.1$ Hz, 4H) or ^1H NMR (600 MHz, CDCl_3) δ 9.75 (s, 1H), 8.95 (d, $J = 1.7$ Hz, 1H), 8.44 (dd, $J = 8.8, 1.8$ Hz, 1H), 8.22 (d, $J = 8.8$ Hz, 1H), 8.04 – 7.94 (m, 4H), 7.58 (dd, $J = 10.4, 4.4$ Hz, 2H), 7.51 (td, $J = 7.6, 3.1$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 171.21, 168.31, 154.33 (d, $J = 122.4$ Hz), 153.52 (d, $J = 123.2$ Hz), 147.95 (d, $J = 21.5$ Hz), 147.22 (d, $J = 22.0$ Hz), 144.45, 144.03 (d, $J = 17.3$ Hz), 141.89, 141.41 (d, $J = 17.3$ Hz), 133.46, 132.86, 132.62, 132.21, 132.17, 132.15, 132.11, 131.97, 131.69, 131.20 (d, $J = 10.9$ Hz), 130.89 (d,

$J = 9.0$ Hz), 130.49, 130.47, 130.18 (d, $J = 8.9$ Hz), 129.94, 128.74, 128.66; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 21.44 or 21.07; HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{16}\text{N}_2\text{O}_3\text{P}[\text{M}+\text{H}]^+$ 375.0893, found 375.0890.




3sa, 80% (1:7.6 mixture)

methyl 2 or 3-(diphenylphosphoryl)quinoxaline-6-carboxylate (3sa). Yield, 80%; ^1H NMR (600 MHz, CDCl_3) δ 9.70 (s, 1H), 8.87 (d, $J = 1.6$ Hz, 1H), 8.40 (dd, $J = 8.8, 1.7$ Hz, 1H), 8.20 (d, $J = 8.8$ Hz, 1H), 7.97 (dt, $J = 11.1, 7.0$ Hz, 4H), 7.57 (dd, $J = 10.7, 4.1$ Hz, 2H), 7.50 (td, $J = 7.6, 3.0$ Hz, 4H), 4.03 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 165.82, 154.50 (d, $J = 121.6$ Hz), 147.22 (d, $J = 21.8$ Hz), 143.85 (d, $J = 17.0$ Hz), 141.94, 133.00, 132.49, 132.48, 132.19, 132.16, 132.10, 131.28, 130.58, 130.44, 130.17, 128.68, 128.60, 52.84; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.54 or 20.24; HRMS (m/z) calcd for $\text{C}_{22}\text{H}_{18}\text{N}_2\text{O}_3\text{P}[\text{M}+\text{H}]^+$ 389.1050, found 389.1055.



3ta-1


(7-chloroquinoxalin-2-yl)diphenylphosphine oxide (3ta-1). Yield, 98%; ^1H NMR (600 MHz, CDCl_3) δ 9.61 (s, 1H), 8.18 (d, $J = 2.2$ Hz, 1H), 8.09 (d, $J = 9.0$ Hz, 1H), 7.95 – 7.90 (m, 4H), 7.77 (dd, $J = 9.0, 2.2$ Hz, 2H), 7.60 – 7.56 (m, 2H), 7.50 (td, $J = 7.6, 3.0$ Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.26 (d, $J = 123.9$ Hz), 147.18 (d, $J = 22.0$ Hz), 142.86, 140.71 (d, $J = 16.8$ Hz), 138.20, 132.55, 132.53, 132.15 (2), 132.08 (2), 132.03, 131.37, 131.24, 131.14 (d, $J = 8.5$ Hz), 130.41, 128.70 (2), 128.62 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 21.42. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{15}\text{ClN}_2\text{OP}[\text{M}+\text{H}]^+$ 365.0605, found 365.0609.




3ta-2

(6-chloroquinoxalin-2-yl)diphenylphosphine oxide (3ta-2). Yield, 98%; ^1H NMR (600 MHz, CDCl_3) δ 9.63 (s, 1H), 8.17 (d, $J = 2.3$ Hz, 1H), 8.13 (d, $J = 9.0$ Hz, 1H), 7.98 – 7.90 (m, 4H), 7.80 (dd, $J = 9.0, 2.3$ Hz, 1H), 7.57 (td, $J = 7.4, 1.3$ Hz, 2H), 7.52 – 7.46 (m, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.51 (d, $J = 122.5$ Hz), 146.43 (d, $J = 21.8$ Hz), 142.34 (d, $J = 17.3$ Hz), 141.05, 136.83, 133.04, 132.45, 132.43, 132.12 (2), 132.06 (2), 131.38, 130.82 (d, $J = 1.8$ Hz), 130.68, 128.90, 128.65 (2), 128.57 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.48. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{15}\text{ClN}_2\text{OP}[\text{M}+\text{H}]^+$


365.0605, found 365.0608.




(7-bromoquinoxalin-2-yl)diphenylphosphine oxide (3ua-1). Yield, 98%; ^1H NMR (600 MHz, CDCl_3) δ 9.61 (s, 1H), 8.37 (d, $J = 2.1$ Hz, 1H), 8.02 (d, $J = 9.0$ Hz, 1H), 7.97 – 7.87 (m, 5H), 7.57 (td, $J = 7.4$, 1.2 Hz, 2H), 7.49 (td, $J = 7.6$, 3.1 Hz, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.73 (d, $J = 123.1$ Hz), 147.18 (d, $J = 21.9$ Hz), 143.06, 140.93 (d, $J = 17.1$ Hz), 134.49, 132.43, 132.41, 132.14 (2), 132.08 (2), 131.91 (d, $J = 1.6$ Hz), 131.38, 131.10 (d, $J = 105.3$ Hz), 128.65 (2), 128.56 (2), 126.45; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.60. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{15}\text{BrN}_2\text{OP}[\text{M}+\text{H}]^+$ 409.0100, found 409.0109.




(6-bromoquinoxalin-2-yl)diphenylphosphine oxide (3ua-2). Yield, 98%; ^1H NMR (600 MHz, CDCl_3) δ 9.65 (s, 1H), 8.35 (d, $J = 2.0$ Hz, 1H), 8.05 (d, $J = 9.0$ Hz, 1H), 7.94 (ddd, $J = 9.0$, 5.6, 4.5 Hz, 4H), 7.57 (td, $J = 7.4$, 1.2 Hz, 2H), 7.52 – 7.44 (m, 4H); ^{13}C NMR (151 MHz, CDCl_3) δ 153.45 (d, $J = 122.4$ Hz), 146.61 (d, $J = 21.7$ Hz), 142.56 (d, $J = 17.3$ Hz), 141.36, 135.50, 132.44, 132.42, 132.31, 132.12 (2), 132.05 (2), 131.06 (d, $J = 105.2$ Hz), 130.90, 128.64 (2), 128.56 (2), 125.00; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.41. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{15}\text{BrN}_2\text{OP}[\text{M}+\text{H}]^+$ 409.0100, found 409.0105.




(7-methylquinoxalin-2-yl)diphenylphosphine oxide (3va-1). Yield, 95%; ^1H NMR (600 MHz, CDCl_3) δ 9.57 (s, 1H), 8.04 (d, $J = 8.6$ Hz, 1H), 7.95 (m, 5H), 7.66 (d, $J = 7.5$ Hz, 1H), 7.55 (t, $J = 7.3$ Hz, 2H), 7.48 (t, $J = 7.1$ Hz, 4H), 2.63 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 161.07 (d, $J = 318.0$ Hz), 146.40 (d, $J = 22.4$ Hz), 143.08, 142.88 (d, $J = 62.2$ Hz), 133.17, 132.22 (2), 132.16 (2), 132.10 (2), 129.72, 128.55 (2), 128.47 (2), 128.26, 29.70; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 19.00; HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 345.1151, found 345.1155.




(6-methylquinoxalin-2-yl)diphenylphosphine oxide (3va-2). Yield, 95%; ^1H NMR (600 MHz, CDCl_3) δ 9.55 (s, 1H), 8.11 (d, $J = 8.6$ Hz, 1H), 8.00 – 7.89 (m, 5H), 7.72 (d, $J = 8.6$ Hz, 1H), 7.56 (dd, $J = 10.6, 4.3$ Hz, 2H), 7.48 (td, $J = 8.0, 2.9$ Hz, 4H), 2.61 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 152.22 (d, $J = 124.8$ Hz), 144.81 (d, $J = 22.4$ Hz), 142.52 (d, $J = 17.1$ Hz), 141.86, 140.29, 134.76, 132.29, 132.27, 132.12 (2), 132.06 (2), 131.34 (d, $J = 105.0$ Hz), 128.86, 128.56 (3), 128.48 (2), 116.35, 21.84; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 18.80; HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{OP}[\text{M}+\text{H}]^+$ 345.1151, found 345.1150.



(7-methoxyquinoxalin-2-yl)diphenylphosphine oxide (3wa-1). Yield, 98%; ^1H NMR (600 MHz, CDCl_3) δ 9.44 (s, 1H), 8.03 (d, $J = 9.2$ Hz, 1H), 7.93 (dd, $J = 11.8, 7.9$ Hz, 4H), 7.55 (t, $J = 7.3$ Hz, 2H), 7.48 (t, $J = 5.9$ Hz, 5H), 7.37 (s, 1H), 3.96 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 161.32, 151.70 (d, $J = 125.1$ Hz), 144.02 (d, $J = 17.9$ Hz), 143.88 (d, $J = 22.7$ Hz), 138.95 (d, $J = 2.1$ Hz), 132.25, 132.23, 132.13 (2), 132.07 (2), 131.38 (d, $J = 104.8$ Hz), 130.34 (d, $J = 1.8$ Hz), 128.55 (2), 128.46 (2), 125.92, 106.80, 55.94; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 19.40; HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_2\text{P}[\text{M}+\text{H}]^+$ 361.1100, found 361.1105.




(6-methoxyquinoxalin-2-yl)diphenylphosphine oxide (3wa-2). Yield, 98%; ^1H NMR (600 MHz, CDCl_3) δ 9.52 (s, 1H), 8.03 (d, $J = 8.9$ Hz, 1H), 7.98 – 7.90 (m, 4H), 7.55 (t, $J = 7.2$ Hz, 2H), 7.51 – 7.45 (m, 6H), 4.00 (s, 3H); ^{13}C NMR (151 MHz, CDCl_3) δ 162.68, 146.08 (d, $J = 23.1$ Hz), 144.03, 132.23 (2), 132.17 (2), 132.11 (2), 131.29, 128.57 (2), 128.49 (2), 124.91, 105.98, 56.18; ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 19.17; HRMS (m/z) calcd for $\text{C}_{21}\text{H}_{18}\text{N}_2\text{O}_2\text{P}[\text{M}+\text{H}]^+$ 361.1100, found 361.1102.



2-(diphenylphosphaneyl)quinoxaline (6). ^1H NMR (600 MHz, CDCl_3) δ 9.64 (s, 1H), 8.25 (dd, $J = 8.3, 0.9$ Hz, 1H), 8.19 (dd, $J = 8.3, 0.8$ Hz, 1H), 8.00 – 7.93 (m, 4H), 7.93 – 7.88 (m, 1H), 7.88 – 7.83

(m, 1H), 7.57 (td, $J = 7.4, 1.2$ Hz, 2H), 7.49 (td, $J = 7.6, 3.1$ Hz, 4H). ^{13}C NMR (151 MHz, CDCl_3) δ 152.63 (d, $J = 124.0$ Hz), 145.55 (d, $J = 22.3$ Hz), 142.49 (d, $J = 17.0$ Hz), 141.58, 132.40 (2), 132.38, 132.17 (2), 132.10 (2), 131.53, 131.05, 130.83, 130.26, 129.07, 128.63 (2), 128.55 (2). ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 20.48. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{P}[\text{M}+\text{H}]^+$ 315.1046, found 315.1045.



diphenyl(quinoxalin-2-yl)phosphine sulfide (7). ^1H NMR (600 MHz, CDCl_3) δ 9.81 (s, 1H), 8.23 (d, $J = 7.5$ Hz, 1H), 8.14 – 8.09 (m, 1H), 8.00 – 7.93 (m, 4H), 7.92 – 7.87 (m, 1H), 7.86 – 7.81 (m, 1H), 7.56 – 7.52 (m, 2H), 7.50 – 7.44 (m, 4H); ^{13}C ^{13}C NMR (151 MHz, CDCl_3) δ 151.84 (d, $J = 104.7$ Hz), 146.01 (d, $J = 27.8$ Hz), 141.51 (d, $J = 16.2$ Hz), 141.07, 132.53 (2), 132.46 (2), 132.36, 131.94, 131.92, 131.69, 131.12, 131.05, 130.23 (d, $J = 1.3$ Hz), 128.97 (d, $J = 2.1$ Hz), 128.54 (2), 128.45 (2); ^{31}P NMR (243 MHz, CDCl_3): δ (ppm) 35.74. HRMS (m/z) calcd for $\text{C}_{20}\text{H}_{16}\text{N}_2\text{PS}[\text{M}+\text{H}]^+$ 347.0766, found 347.0765.

3. NMR spectrum of **3**, **6** and **7**




Fig.S 1 ¹H NMR of compound **3aa**




Fig.S 2 ¹³C NMR of compound **3aa**




Fig.S 3 ^{31}P NMR of compound 3aa




Fig.S 4 ^1H NMR of compound 3aa'




Fig.S 5 $^1\text{H NMR}$ of compound **3ab**




Fig.S 6 $^{13}\text{C NMR}$ of compound **3ab**




Fig.S 7 ^{31}P NMR of compound 3ab




Fig.S 8 ^{19}F NMR of compound 3ab




Fig.S 9 ^1H NMR of compound 3ac




Fig.S 10 ^{13}C NMR of compound 3ac




Fig.S 11 ³¹P NMR of compound 3ac




Fig.S 12 ¹⁹F NMR of compound 3ac




Fig.S 13 $^1\text{H NMR}$ of compound 3ad




Fig.S 14 $^{13}\text{C NMR}$ of compound 3ad




Fig.S 15 ^{31}P NMR of compound 3ad




Fig.S 16 ^1H NMR of compound 3ae




Fig.S 17 ¹³C NMR of compound 3ae




Fig.S 18 ³¹P NMR of compound 3ae




Fig.S 19 ^1H NMR of compound 3af




Fig.S 20 ^{13}C NMR of compound 3af




Fig.S 21 ^{31}P NMR of compound 3af




Fig.S 22 ^1H NMR of compound 3ag




Fig.S 23 ¹³C NMR of compound **3ag**




Fig.S 24 ³¹P NMR of compound **3ag**




Fig.S 25 ¹H NMR of compound 3ah




Fig.S 26 ¹³C NMR of compound 3ah




Fig.S 27 ^{31}P NMR of compound 3ah




Fig.S 28 ^1H NMR of compound 3ai




Fig.S 29 ^{13}C NMR of compound 3ai




Fig.S 30 ^{31}P NMR of compound 3ai




Fig.S 31 $^1\text{H NMR}$ of compound 3aj




Fig.S 32 $^{13}\text{C NMR}$ of compound 3aj




Fig.S 33 ^{31}P NMR of compound 3aj




Fig.S 34 ^1H NMR of compound 3ak




Fig.S 35 ^{13}C NMR of compound **3ak**




Fig.S 36 ^{31}P NMR of compound **3ak**




Fig.S 37 $^1\text{H NMR}$ of compound 3am




Fig.S 38 $^{13}\text{C NMR}$ of compound 3am




Fig.S 39 ^{31}P NMR of compound 3am




Fig.S 40 ^1H NMR of compound 3am




Fig.S 41 ^{13}C NMR of compound 3an




Fig.S 42 ^{31}P NMR of compound 3an




Fig.S 43 $^1\text{H NMR}$ of compound 3ao




Fig.S 44 $^{13}\text{C NMR}$ of compound 3ao




Fig.S 45 ^{31}P NMR of compound 3ao




Fig.S 46 ^1H NMR of compound 3ap




Fig.S 47 ^{13}C NMR of compound 3ap




Fig.S 48 ^{31}P NMR of compound 3ap




Fig.S 49 $^1\text{H NMR}$ of compound 3aq




Fig.S 50 $^{13}\text{C NMR}$ of compound 3aq




Fig.S 51 ^{31}P NMR of compound 3aq




Fig.S 52 ^1H NMR of compound 3ca




Fig.S 53 ¹³C NMR of compound 3ca




Fig.S 54 ³¹P NMR of compound 3ca




Fig.S 55 ¹H NMR of compound 3da




Fig.S 56 ¹³C NMR of compound 3da




Fig.S 57 ³¹P NMR of compound 3da




Fig.S 58 ¹H NMR of compound 3ea




Fig.S 59 ^{13}C NMR of compound 3ea




Fig.S 60 ^{31}P NMR of compound 3ea




Fig.S 61 ¹H NMR of compound 3fa




Fig.S 62 ¹³C NMR of compound 3fa




Fig.S 63 ^{31}P NMR of compound 3fa




Fig.S 64 ^1H NMR of compound 3ga




Fig.S 65 ^{13}C NMR of compound 3ga




Fig.S 66 ^{31}P NMR of compound 3ga




Fig.S 67 ^1H NMR of compound 3ha




Fig.S 68 ^{13}C NMR of compound 3ha




Fig.S 69 ^{31}P NMR of compound 3ha




Fig.S 70 ^1H NMR of compound 3ia




Fig.S 71 ¹³C NMR of compound 3ia




Fig.S 72 ³¹P NMR of compound 3ia




Fig.S 73 ^1H NMR of compound 3ja




Fig.S 74 ^{13}C NMR of compound 3ja




Fig.S 75 ^{31}P NMR of compound 3ja




Fig.S 76 ^1H NMR of compound 3ka




Fig.S 77 ¹³C NMR of compound 3ka




Fig.S 78 ³¹P NMR of compound 3ka




Fig.S 79 ¹H NMR of compound 3la-1




Fig.S 80 ¹³C NMR of compound 3la-1




Fig.S 81 ^{31}P NMR of compound 3la-1




Fig.S 82 ^1H NMR of compound 3la-2




Fig.S 83 ¹³C NMR of compound 3Ia-2




Fig.S 84 ³¹P NMR of compound 3Ia-2




Fig.S 85 ¹H NMR of compound 3ma-1




Fig.S 86 ¹³C NMR of compound 3ma-1




Fig.S 87 ^{31}P NMR of compound 3ma-1




Fig.S 88 ^1H NMR of compound 3ma-2




Fig.S 89 ¹³C NMR of compound 3ma-2




Fig.S 90 ³¹P NMR of compound 3ma-2




Fig.S 91 $^1\text{H NMR}$ of compound 3na-1




Fig.S 92 $^{13}\text{C NMR}$ of compound 3na-1




Fig.S 93 ^{31}P NMR of compound 3na-1




Fig.S 94 ^1H NMR of compound 3na-2




Fig.S 95 ¹³C NMR of compound 3na-2




Fig.S 96 ³¹P NMR of compound 3na-2




Fig.S 97 $^1\text{H NMR}$ of compound **30a-1**




Fig.S 98 $^{13}\text{C NMR}$ of compound **30a-1**




Fig.S 99 ^{31}P NMR of compound 30a-1




Fig.S 100 ^1H NMR of compound 30a-2




Fig.S 101 ^{13}C NMR of compound **30a-2**




Fig.S 102 ^{31}P NMR of compound **30a-2**




Fig.S 103 ¹H NMR of compound 3pa-1




Fig.S 104 ¹³C NMR of compound 3pa-1




Fig.S 105 ^{31}P NMR of compound 3pa-1




Fig.S 106 ^1H NMR of compound 3pa-2




Fig.S 107 ¹³C NMR of compound 3pa-2




Fig.S 108 ³¹P NMR of compound 3pa-2




Fig.S 109 ^1H NMR of compound 3qa




Fig.S 110 ^{13}C NMR of compound 3qa




Fig.S 111 ^{31}P NMR of compound 3qa




Fig.S 112 ^1H NMR of compound 3ra




Fig.S 113 ^{13}C NMR of compound 3ra




Fig.S 114 ^{31}P NMR of compound 3ra




Fig.S 115 ^1H NMR of compound 3sa




Fig.S 116 ^{13}C NMR of compound 3sa




Fig.S 117 ^{31}P NMR of compound 3sa




Fig.S 118 ^1H NMR of compound 3ta-1




Fig.S 119 ^{13}C NMR of compound 3ta-1




Fig.S 120 ^{31}P NMR of compound 3ta-1




Fig.S 121 $^1\text{H NMR}$ of compound 3ta-2




Fig.S 122 $^{13}\text{C NMR}$ of compound 3ta-2




Fig.S 123 ^{31}P NMR of compound 3ta-2




Fig.S 124 ^1H NMR of compound 3ua-1




Fig.S 125 ^{13}C NMR of compound 3ua-1






Fig.S 126 ^{31}P NMR of compound 3ua-1

Fig.S 127 ^1H NMR of compound 3ua-2Fig.S 128 ^{13}C NMR of compound 3ua-2




Fig.S 129 ^{31}P NMR of compound 3ua-2




Fig.S 130 ^1H NMR of compound 3va-1




Fig.S 131 ¹³C NMR of compound **3va-1**




Fig.S 132 ³¹P NMR of compound **3va-1**




Fig.S 133 $^1\text{H NMR}$ of compound 3va-2




Fig.S 134 $^{13}\text{C NMR}$ of compound 3va-2




Fig.S 135 ^{31}P NMR of compound 3va-2




Fig.S 136 ^1H NMR of compound 3wa-1




Fig.S 137 ¹³C NMR of compound 3wa-1




Fig.S 138 ³¹P NMR of compound 3wa-1




Fig.S 139 ¹H NMR of compound 3wa-2




Fig.S 140 ¹³C NMR of compound 3wa-2




Fig.S 141 ^{31}P NMR of compound 3wa-2




Fig.S 142 ^1H NMR of compound 6




Fig.S 143 ^{13}C NMR of compound 6




Fig.S 144 ^{31}P NMR of compound 6




Fig.S 145 ^1H NMR of compound 7




Fig.S 146 ^{13}C NMR of compound 7




Fig.S 147 ^{31}P NMR of compound 7